Molnupiravir tablets for cats are a type of medication designed to address certain health issues in feline companions, particularly those related to viral infections such as feline infectious peritonitis (FIP). FIP is a serious and often fatal disease caused by a mutation of the feline coronavirus.
These tablets contain Molnupiravir, an antiviral agent. The working mechanism of Molnupiravir involves interfering with the replication process of the virus. It is incorporated into the viral RNA during replication, leading to an increased rate of mutations. These mutations are so numerous that they prevent the virus from being able to replicate effectively, thus suppressing the spread of the virus within the cat's body.
One of the key advantages of Molnupiravir tablets for cats is their potential to offer a treatment option for a disease that has previously been difficult to manage. When administered at the appropriate dosage, determined by a veterinarian based on the cat's weight, age, and overall health condition, they can help alleviate symptoms associated with FIP. Symptoms such as fever, loss of appetite, lethargy, and abdominal swelling may improve over time with proper treatment.
| Technical Parameter | Value |
|---|---|
| Generic Name | EIDD-2801 (2349386-89-4) |
| Indication | Treatment of COVID-19 (Cat FIP Treatment) |
| Specification | 3 KG |
| Shipping Method | Air (UPS, FedEx, TNT, EMS) or Sea |
| Shelf Life | 2 years |
| Purity | 99% |
| CAS | 2349386-89-4 |
| COA | Available |
Function:
Molnupiravir Tablets play a pivotal role in the treatment of feline infectious peritonitis (FIP) in cats. FIP is caused by a mutated form of the feline coronavirus. The primary function of Molnupiravir is to interfere with the virus's replication machinery.
Once ingested by the cat, Molnupiravir is metabolized into its active form, which is then incorporated into the viral RNA during replication. This incorporation leads to a high rate of mutations in the viral genome. As the virus tries to replicate, these mutations accumulate, causing errors in the synthesis of essential viral proteins. The result is a significant reduction in the production of viable virus particles.
By curbing the virus's ability to replicate effectively, Molnupiravir Tablets can slow down the progression of FIP. This, in turn, helps alleviate the symptoms associated with the disease. Cats suffering from FIP often experience lethargy, loss of appetite, weight loss, and fluid accumulation. As the virus replication is inhibited, the body's immune system can better cope with the existing virus load. This can lead to an improvement in the cat's overall condition, with reduced fluid build - up in the abdomen or chest, increased energy levels, and a return of normal appetite. In essence, Molnupiravir Tablets offer a fighting chance for cats with FIP by targeting the root cause of the disease at the molecular level.
